After H.C. Wainwright and Chardan Capital gave Krystal Biotech Inc (NASDAQ: KRYS) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Elemer Piros maintained a Buy rating on Krystal Biotech Inc today and set a price target of $34. The company’s shares closed yesterday at $25.07.
“We rate Krystal Biotech Overweight. Krystal focuses on developing and delivering gene therapy products for dermatological diseases. Its lead program, KB103, is in Phase 2 development for the treatment of dystrophic epidermolysis bullosa. Valuation Summary The probability adjusted, fully-taxed (21%) NPV (15% discount rate) of potential cash flows through 2032 is $355 million, or ~$24 per share. Including a technology value of $50 million (~$3/share) and our estimate of 2019 YE cash of $88 million (~$6/share), we arrive at our valuation of $493 million or $34/share.”
According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.1% and a 35.3% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
Krystal Biotech Inc has an analyst consensus of Strong Buy, with a price target consensus of $38.67.
The company has a one-year high of $28.75 and a one-year low of $8.61. Currently, Krystal Biotech Inc has an average volume of 88.61K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KRYS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.